Welcome to our dedicated page for Jazz Pharmaceuticals plc SEC filings (Ticker: JAZZ), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Jazz Pharmaceuticals plc's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Jazz Pharmaceuticals plc's regulatory disclosures and financial reporting.
Jazz Pharmaceuticals plc, through its wholly owned subsidiary Jazz Lux, amended its credit agreement to reprice and extend the maturity of its U.S. dollar term loans. Certain existing lenders converted Tranche B-2 loans into Tranche B-3 loans, and Jazz Lux borrowed an additional $273,310,355.18 to repay B-2 loans that were not converted. Outstanding principal totaled $1.895 billion immediately before the amendment and after it.
The new tranche matures May 5, 2033, extended from May 5, 2028. Its applicable margins are 1.75% for Term SOFR borrowings and 0.75% for borrowings at the prime lending rate, a decrease of 50 basis points from B-2. The loans amortize in quarterly installments equal to 0.25% of initial principal, with the remaining balance payable at maturity. They have a 0.50% Term SOFR floor and no credit spread adjustment.
Jazz Pharmaceuticals plc (JAZZ) completed the acquisition of Actio Biosciences, Inc. for $820 million upfront, making Actio a wholly owned subsidiary through a merger with an indirect Jazz subsidiary. The transaction adds ABS-1230, a clinical-stage, orally available KCNT1 inhibitor for KCNT1-related epilepsy.
ABS-1230 has shown meaningful seizure reductions in an early clinical proof-of-concept trial in children and is described as a potential first-in-class precision therapy. It has received Fast Track, Rare Pediatric Disease and Orphan Drug Product designations from the U.S. FDA and entered the agency’s Rare Disease Evidence Principles process.
As part of the deal, certain non-ABS-1230 programs were transferred into a new privately held company funded by existing Actio investors, with Jazz receiving a minority equity stake and related rights, while focusing its ownership of Actio on ABS-1230.
Jazz Pharmaceuticals plc (JAZZ) reported that Executive Vice President and Chief Legal Officer Neena M. Patil sold 1,200 ordinary shares on September 10, 2026 at an average price of $240.94 per share in an open-market or private transaction. The sale occurred automatically under a Rule 10b5-1 trading plan adopted on February 26, 2026 and is described as non-discretionary. Following this transaction, Patil directly holds 47,671 ordinary shares of Jazz Pharmaceuticals.
Jazz Pharmaceuticals plc (JAZZ) reported insider activity by President & CEO Renee D. Gala on September 8, 2026. Gala had 1,967 ordinary shares withheld to satisfy tax obligations arising from the vesting of previously granted restricted stock units, and separately sold 2,000 ordinary shares at $243.03 per share in a sale described as an open market or private transaction made automatically under a Rule 10b5-1 trading plan adopted on June 4, 2026.
Jazz Pharmaceuticals plc (JAZZ) reported that officer Mary Elizabeth Henderson, Senior Vice President of Technical Operations, disposed of ordinary shares on September 8, 2026 to cover tax obligations from vesting restricted stock units. A total of 1,427 shares were delivered or withheld for payment of tax liability, and no Rule 10b5-1 trading plan is reported.
Jazz Pharmaceuticals plc (JAZZ) received a notice that officer Neena Patil plans to sell 1,200 shares of common stock under Rule 144. The shares were acquired as restricted stock from the issuer on March 5, 2026 and are proposed to be sold on September 10, 2026 on NASDAQ.
The filing lists an aggregate market value of $289,128 for the planned sale through Morgan Stanley Smith Barney LLC Executive Financial Services.
Jazz Pharmaceuticals plc (JAZZ) received a notice that officer Renee D. Gala plans to sell up to 2,000 shares of the company’s common stock under Rule 144. The shares, described as Restricted Stock, were acquired on June 30, 2026 and are to be sold through Morgan Stanley Smith Barney LLC, with a stated aggregate market value of $486,060 as of September 8, 2026.
Jazz Pharmaceuticals plc (JAZZ) reports that director Mary Elizabeth Henderson has filed a notice of proposed sale of 2,691 shares of common stock under Rule 144. A prior sale during the last three months involved 2,092 common shares with a reported transaction amount of 504,898.00.
Jazz Pharmaceuticals plc (JAZZ) reported that officer Mary Elizabeth Henderson, SVP, Technical Operations, had shares withheld on August 31, 2026 to cover taxes from the vesting of previously granted restricted stock units. Two transactions disposed of a total of 2,092 Ordinary Shares at per‑share prices around the mid‑$240s.
Jazz Pharmaceuticals plc (JAZZ) reported that director Mark Douglas Smith had shares withheld on August 31, 2026 to cover tax obligations from the vesting of previously granted restricted stock units. A total of 1,706 Ordinary Shares were disposed of through tax-withholding transactions at prices around the mid-$240s per share. No Rule 10b5-1 trading plan is reported.